the aetiology of chronic hypertension is not well understood. we have developed a new, effective and safe oral coronavirus drug candidate, b-343, and we have initiated two ongoing phase 2a clinical trials with 729 nucleoside analog therapy and vaccitech's therapeutic vaccine. we anticipate that this new compound will be a new and promising target for coronavirus infection.